Friday, July 10, 2026

biotech · HER2 Positive Breast Cancer

Prestige BioPharma

Prestige Biopharma Belgium is a biotech organization headquartered in EU. Primary therapeutic focus areas include HER2 Positive Breast Cancer. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent r

Seoul, KR HQ
1 Employees
EMA registrant Type
Company details
Status
Public
HQ
Seoul, KR
Employees
1
Programs
2
Drugs
0
Patents
0
Clinical program

HD201

Phase 3 · small molecule · HER2 Positive Breast Cancer

HD201 for HER2 Positive Breast Cancer is a Phase 3 program (small_molecule) at Prestige Biopharma Belgium with 1 ClinicalTrials.gov record(s).

← All Prestige Biopharma Belgium projects Phase 3 small molecule completed

Internal code TROIKA

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Prestige Biopharma Belgium
Phase
Phase 3
Modality
small_molecule
Indication
HER2 Positive Breast Cancer
Status
completed
Trials
1

Clinical trials